[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sarcoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sarcoma":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,139,0,25,[9,41,65,93,135,167,202,281,306,336,365,407,427,456,480,514,537,562,591,617,636,661,683,711,736],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100191818","molecular-testing-for-the-md-anderson-cancer-center-personalized-cancer-therapy-program-100191818",false,"NCT01772771","Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program","Inclusion Criteria:\n\n* Patients must have histologically, radiographic, or cytologically documented cancer, suspected glioma, sarcoma, melanoma or hematologic cancer. Patients with benign tumors may also be consented at the discretion of the attending physician if molecular profiling is felt to have potential clinical implications.\n* Patients must have the ability to understand and the willingness to sign a written informed consent document\n* Patients may be consented without confirming the amount and quality of archival diagnostic or residual tissue available. However, research testing will only be performed on patients who have sufficient archived diagnostic tissue or residual tissue banked in one of the authorized tissue banks at MD Anderson available to proceed with testing. The extent of testing may be modified based on amount of tissue available. If any new tissue acquisition including a biopsy and\u002For surgical resection etc. is being ordered for clinical care or another research study, or an operation is being performed testing can be ordered on that sample\n* Circulating cell-free deoxyribonucleic acid (cfDNA) Cohort: Circulating cell-free DNA next generation sequencing (NGS) testing will be performed with the Clinical Laboratory Improvement Act (CLIA)-certified Guardant360 panel (or equivalent) for select patients. This particular cohort of research collaboration will be supported by Guardant Health, Inc. at no charge to MD Anderson. Patients who are being considered for enrollment into clinical trials in the next 2 lines of therapy may be enrolled. Selected patients may have cfDNA, circulating RNA \u002Fexosome\u002Fcirculating tumor cell testing approaches performed on alternate platforms (eg Foundation ACT)","ALL",{"count":18,"type":19},12000,"ESTIMATED","OBSERVATIONAL","This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson. This may help doctors use testing information on tumors to identify clinical trials that may be most relevant to patients. Researchers may also use the information learned from this study to develop a database of the different kinds of mutations in cancer-related genes.",[23,24,25,26,27],"Glioma","Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","Melanoma","Sarcoma","RECRUITING","2026-08-20",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":32},"2012-03-01",{"date":36,"type":19},"2033-03-01",{"name":38,"class":39},"M.D. Anderson Cancer Center","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100397903","enhanced-recovery-after-surgery-in-extremity-sarcoma-100397903","NCT04461171","Enhanced Recovery After Surgery in Extremity Sarcoma","Inclusion Criteria:\n\n* Any patient at Vanderbilt University Medical Center treated with surgical excision of a suspected extremity sarcoma\n* Adult patients \\>17 years of age\n* Patients of all preoperative opioid status (naïve or dependent)\n\nExclusion Criteria:\n\n* Patients treated non-operatively\n* Non-English speaking patients","18 Years",{"count":49,"type":19},120,"INTERVENTIONAL",[52],"NA","The purpose of this study is to demonstrate the efficacy of implementing the enhanced recovery after surgery (ERAS) pathway in a prospective manner to patients undergoing surgical treatment for extremity sarcoma.",[27],[56],"Enhanced Recovery After Surgery","2026-08-19",{"date":31,"type":32},{"date":60,"type":32},"2020-12-14",{"date":62,"type":19},"2026-12",{"name":64,"class":39},"Joshua Lawrenz",{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":50,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100517752","phase-1-a-study-of-crd3874-si-in-people-with-solid-tumors-100517752","NCT06021626","A Study of CRD3874-SI in People With Solid Tumors","A Phase I Trial of CRD3874-SI, a STING Agonist, in Patients With Advanced\u002FMetastatic Malignant Solid Tumors","Inclusion Criteria:\n\n* Male or female age ≥ 18 years at the time of informed consent.\n* Be capable, willing, and able to provide written informed consent.\n* Be willing to comply with clinical trial instructions and requirements, including tumor biopsies (if feasible and required per protocol).\n* Patients must have a locally advanced or metastatic cancer, a malignant solid tumor that has progressed on at least one line of systemic therapy or for which no standard treatment is available, the participant is intolerant to available treatment, or the participant declined standard of care systemic therapy.\n* In the dose escalation phase study patients with the following tumor types will be eligible: Of note patients who declined or were intolerable of standard of care systemic therapy will be considered in all dose expansion cohorts.\n* Head and neck squamous cell carcinoma (HNSCC)\n* Participants must have histologically or cytologically confirmed recurrent and\u002For metastatic HNSCC and must have received 1-2 prior lines of systemic anti-cancer therapy including a checkpoint inhibitor (patients treated initially with immune checkpoint blockade alone followed by the addition of other drugs in combination \\[i.e., cytotoxic chemotherapy or EGFR inhibitor\\], will be considered 1 line of therapy.\n* HPV positive (p16 IHC positive or HPV RNA ISH positive), PD-L1 CPS score high (≥1)\n* HPV negative (p16 IHC negative or HPV RNA ISH negative), PD-L1 CPS score high (≥1)\n* Adenoid cystic carcinoma (ACC)\n* Participants must have histologically or cytologically confirmed recurrent and\u002For metastatic ACC (cancers arising from non-salivery gland primary sites are eligible) and may have received none or up 2 prior lines of systemic anti-cancer therapy.\n* Merkel cell carcinoma (MCC)\n* Participants must have histologically or cytologically confirmed recurrent and or metastatic MCC and must have received at least one but no more than 3 prior lines of systemic anti-cancer therapy including a checkpoint inhibitor and may not have received prior chemotherapy for MCC.\n* Monotherapy alone\n* Radiation therapy\n* Patients will receive palliative radiation therapy to a tumor site if they have at least one other site of measureable disease that can be chosen as the target lesion to assess response to investigational therapy.\n* Sarcoma that has demonstrated clinical benefit or an objective response to immune checkpoint blockade or sarcoma subtypes that are considered immunogenic subtypes including but not limited to undifferentiated pleomorphic (UPS) or myxofibrosarcoma (MFS), angiosarcoma, alveolara soft part sarcoma, or undifferentiated sarcoma will be considered.\n* Melanoma\n* Uveal Melanoma\n* Participants must have histologically or cytologically confirmed recurrent and\u002For metastatic uveal melanoma and received at least one but no more than two prior lines of systemic anti-cancer therapy including tebentafusp (if HLA-A 02:01+, unless patient declined or was deemed ineligible) and\u002For immune checkpoint inhibitor. Melphalan PHP will count as a line of therapy if give on its own. Unlimited partial hepatic directed therapy will be permitted.\n* Mucosal and Acral melanoma\n* Participants must have histologically or cytologically confirmed recurrent and\u002For metastatic mucosal or acral melanoma and received at least one but no more than two prior lines of systemic anti-cancer therapy including prior exposure to immune checkpoint inhibition. Patients treated with BRAF-MEK therapy may have up to 3 prior lines of therapy.\n* Non small cell lung cancer\n* Participants must have histologically or cytologically confirmed locally advanced\u002Fmetastatic non-small cell lung cancer with prior exposure to immune checkpoint inhibition and received at least one but no more than 2 prior lines of systemic anti-cancer therapy.\n* Participants must have histologically or cytologically confirmed locally advanced\u002Fmetastatic sarcoma and must have received at least one but no more than 2 prior lines of systemic anti-cancer therapy. Patients will receive palliative radiation therapy to a tumor site if they have at least one other site of measureable disease that can be chosen as the target lesion to assess response to investigational therapy\n* Adequate performance status: ECOG 0 or 1\u002FKPS 100-70%.\n* Life expectancy of at least three months after the first CRD3874 infusion, according to the Investigator's opinion\n* Presence of measurable disease per RECIST v1.1.Target lesion(s) must not be chosen from a previously irradiated field unless there has been radiographically and\u002For pathologically documented tumor progression in that lesion prior to enrollment.\n* In the dose expansion phase , participants must agree to have a pretreatment tumor biopsy for research purposes. Participants in whom biopsy is technically not feasible or in whom the associated procedure would result in unacceptable risk, in the opinion of the Investigator, or patients who do not wish to have a biopsy, archival tissue (most recently procured sample where tissue is available) may be used instead, if available.\n* In the dose expansion phase , participants must agree to on-treatment tumor biopsy for research purposes. Participants in whom biopsy is technically not feasible or in whom would result in unacceptable risk, in the opinion of the Investigator, or patients who do not wish to have a biopsy- may be exempted from the biopsy requirement with discussion with the Principal Investigator .\n* Female subject of childbearing potential (defined as a sexually mature female who has not undergone a hysterectomy or bilateral oophorectomy or who has not been naturally postmenopausal for at least 24 consecutive months) should have a negative serum pregnancy testing at screening visit and within 72 hours prior to the first dose of study medication.\n* Adequate organ function determined within 14 days of treatment initiation, defined as follows:\n\n  * Hemoglobin ≥ 9.0 g\u002FdL\n  * Absolute neutrophil count ≥ 1,000\u002Fmm\\^3 (1.0 x 10\\^9\u002FL)\n  * Platelet count ≥ 100,000\u002Fmm3 (100 x 10\\^9 \u002FL)\n  * Serum bilirubin ≤ 1.2x upper limit of normal (ULN) OR direct bilirubin ≤ ULN for participants with total bilirubin level \\> 1.2x ULN\n  * Aspartate aminotransferase (AST) ≤ 2.5x ULN OR ≤ 5x ULN for participants with liver metastases\n  * Alanine aminotransferase (ALT) ≤ 2.5x ULN OR ≤ 5x ULN for participants with liver metastases\n  * Albumin ≥ 2.5mg\u002FdL.\n  * Calculated creatinine clearance (CrCl) ≥ 50 mL\u002Fmin by Cockcroft-Gault formula or CKD-EPI 2021\n  * International Normalized Ratio (INR) or prothrombin time (PT) ≤1.5x ULN unless participant is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants.\n  * Activated partial thromboplastin time (aPTT) ≤ 1.5x ULN unless participant is receiving anticoagulant therapy as long as PT and PTT is within therapeutic range of intended use of anticoagulants\n  * Left ventricular ejection fraction (LVEF) \\> 50%, as measured by echocardiogram (2D-ECHO) or multi-gated acquisition scan (MUGA)\n\nExclusion Criteria:\n\n* Known prior severe hypersensitivity to an investigational product or any component of the study drug therapy's formulations including polyethylene glycol (PEG), (NCI CTCAE v5.0 Grade ≥ 3)\n* Evidence of clinically significant immunosuppression such as the following:\n\n  * Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease\n  * Concurrent opportunistic infection\n  * Receiving systemic immunosuppressive therapy (\\> 2 weeks) including oral steroid doses \\> 10 mg\u002Fday of prednisone or equivalent within 7 days prior to enrollment. In the setting of non-immune mediated indications for use, chronic\u002Factive low dose steroid (equivalent to \\\u003C\u002F=10mg\u002Fday prednisone) use may be permitted at the discretion of the principal investigator.\n  * Current use of immunosuppressive medication, EXCEPT for the following:\n\nI. Intranasal, inhaled, ocular, topical steroids, or local steroid injection (e.g., intraarticular injection) II. Systemic corticosteroids at physiologic doses ≤ 10 mg\u002Fday of prednisone or equivalent III. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n\n* Prior organ transplantation, including allogenic stem-cell transplantation. Consideration will be given to allow patients with a history of autologous transplantation enroll if they are at least 5 years beyond the completion of the transplant pending discussion with the principal investigator.\n* History or evidence of symptomatic autoimmune disease (e.g., pneumonitis, glomerulonephritis, vasculitis, or other), or history of active autoimmune disease that has required systemic treatment (i.e., use of corticosteroids, immunosuppressive drugs or biological agents used for treatment of autoimmune diseases) in past 2 years prior to enrollment. Replacement therapy (e.g., thyroxine for hypothyroidism, insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment for autoimmune disease.\n* Systemic antibiotics received ≥ 7 days prior to the first dose of study drugs.\n* Uncontrolled medical condition including current active infection requiring systemic therapy or symptomatic congestive heart failure within 6 months that in the investigators opinion compromise the ability of the patient to complete all study related requirements safely\n* Inability to comply with protocol required procedures\n* Resting QTc interval by Friderica's formula ≥ 470 ms on a 12-lead electrocardiogram (ECG) for males and females\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment or 5 half-lives, if shorter.\n* Has had prior chemotherapy or targeted small molecule therapy within 3 weeks, anti-cancer monoclonal antibody (mAb) within 4 weeks or OR 5 half-lives, if shorter, or radiation therapy within 2 weeks prior to the first CRD3874 infusion prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent\n\n  * Note: Alopecia or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable\n  * Note: If patient received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting study therapy\n* Evidence of clinically significant interstitial lung disease, history of interstitial lung disease, or active, noninfectious pneumonitis related to prior immunotherapy treatment.\n* History of unstable or deteriorating cardiovascular disease within the previous 6 months prior to screening including but not limited to the following:\n\n  * Unstable angina or myocardial infarction\n  * CVA\u002Fstroke\n  * Congestive heart failure (New York Heart Association \\[NYHA\\] Class III or IV\n  * Uncontrolled clinically significant arrhythmias.\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n* Patients with previously treated brain metastases or carcinomatous meningitis may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment.\n* Has received a live vaccine within 30 days of the planned start of study drug. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.\n* Patients known to be positive for active Hepatitis B (HBsAg reactive with detectable HBV DNA), or Hepatitis C (HCV RNA (qualitative) is detected)\n\n  1. Patients with chronic hepatitis B (positive HBsAg and\u002For HBcAb and negative HBV DNA by PCR) are eligible for this study if they are on suppressive anti-viral therapy and deemed safe by a gastroenterologist\n  2. Patient who is HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution will be considered eligible.\n* Known history of human immunodeficiency virus (HIV) (HIV 1\u002F2 antibodies) disease that is not controlled. Note HIV-positive patients will be considered eligible if:\n\n  * Established ART for at least four weeks and have an HIV viral load less than 400 copies\u002FmL prior to enrollment\n  * CD4+ T-cell (CD4+) counts ≥ 350 cells\u002FuL\n  * No opportunistic infection within the past 12 months\n  * Has a known history of active TB (Bacillus Tuberculosis)\n* Women who are pregnant or breastfeeding\n* Patients expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through three months after the last dose of study treatment(s).\n* Female participants of childbearing potential and male participants who are unwilling to use acceptable method(s) of effective contraception during study treatment and until six months for female and three months for males after the last dose of CRD3874-SI. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.\n\n(Note: Women not of childbearing potential are defined as: Any female who is postmenopausal \\[age \\> 55 years with cessation of menses for 12 or more months or less than 55 years but with no spontaneous menses for at least two years or less than 55 years and spontaneous menses within the past one year but currently amenorrheic (e.g., spontaneous or secondary to hysterectomy) and with postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels \\> 40 IU\u002FL) or postmenopausal estradiol levels (\\\u003C 5 ng\u002FdL) or according to the definition of \"postmenopausal range\" for the laboratory involved\\] or who have had a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.)\n\n* The presence of a concurrent active malignancy that in the opinion of the investigator could compromise the conduct of the study or interfere with determining the outcomes of the study objectives.\n* History of non-infectious colitis.",{"count":73,"type":19},81,[75],"PHASE1","This study will test the safety of a study drug called CRD3874-SI. The researchers will test different doses of CRD3874-SI to find the highest dose that causes few or mild side effects in participants. After the researchers find the highest safe dose of CRD3874-SI, they will test that dose in new groups of participants to help them learn more about the side effects of the study drug and find out whether CRD3874-SI is an effective treatment for for patients with advanced or metastatic malignant solid tumors including sarcoma and Merkel Cell Carcinoma. (MCC), Head and neck squamous cell carcinoma (HNSCC), Adenoid cycstic carcinoma (ACC), Uveal Melanoma, Muscosal and Acral melanoma, and Non small cell lung cancer. The researchers will also look at how the body absorbs, distributes, and gets rid of CRD3874-SI, and the how the body and immune system respond to CRD3874-SI.",[27,78],"Merkel Cell Carcinoma",[80,81,82],"CRD3874-SI","23-169","Advanced\u002FMetastatic Malignant Solid Tumors","2026-08-11",{"date":85,"type":32},"2026-08-13",{"date":87,"type":32},"2023-08-25",{"date":89,"type":19},"2029-08",{"name":91,"class":39},"Memorial Sloan Kettering Cancer Center",7,{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":50,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":134},"100534718","phase-1-a-study-of-mgc026-in-participants-with-advanced-solid-tumors-100534718","NCT06242470","A Study of MGC026 in Participants With Advanced Solid Tumors","A Phase 1\u002F1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Adults ≥ 18 years old, able to provide informed consent\n* Adequate performance and laboratory parameters\n* Availability of archival or formalin-fixed paraffin-embedded tumor tissue sample. Participants may undergo a fresh tumor biopsy to obtain a specimen for testing if an archival tumor sample is not available. Participants with no available archival tissue sample who cannot safely undergo a fresh biopsy as determined by consultation between the sponsor and investigator are eligible\n* Unresectable, locally advanced or metastatic solid tumors including: squamous cell cancer (SCC) of the head and neck, esophageal SCC, squamous and non-squamous non-small cell lung cancer, small cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, castration resistant prostate cancer, breast cancer, ovarian cancer, cervical cancer, colorectal cancer gastric or gastroesophageal cancer, pancreatic carcinoma, clear cell renal cell cancer or hepatocellular cancer.\n* Measurable disease per RECIST v1.1. Participants with metastatic CRPC without measurable disease are eligible.\n* Must be willing to use highly effective methods of birth control from the time of consent through 7 months after discontinuation of MGC026.\n* Not pregnant or breastfeeding.\n\nExclusion Criteria:\n\n* Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.\n* Another cancer that required treatment within the past 2 years, with the exception of those with low risk of cancer spreading or death such as adequately treated non melanomatous skin cancer, localized prostate cancer (Gleason Score \\\u003C 6), or carcinoma in situ.\n* Patients with history of prior central nervous system (CNS) metastasis must have been treated, be asymptomatic, and not have concurrent treatment for CNS disease, progression of CNS metastases on magnetic resonance imaging, computed tomography or positron emission tomography, or history of leptomeningeal disease or cord compression at the time of enrollment.\n* Treatment with surgery, systemic cancer therapy, immunotherapy, chimeric antigen receptor-T therapy, or anti-hormonal within protocol specified intervals.\n* Prior treatment with any B7-H3 targeted agent for cancer or any ADC with a topoisomerase payload.\n* Prior autologous or allogeneic stem cell or solid organ transplant.\n* Clinically significant cardiovascular, pulmonary, or gastrointestinal disorders.\n* Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 1 week of first study drug administration.\n* Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction.\n* Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.\n* History of primary immunodeficiency.\n* Major trauma or major surgery within 4 weeks of first study drug administration.\n* Known hypersensitivity to recombinant proteins.",{"count":101,"type":19},250,[75],"The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study.\n\nParticipants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.",[105,106,107,108,109,110,111,27,112,26,113,114,115,116,117,118,119,120,121,122,123,124],"Advanced Solid Tumor","Advanced Cancer","Metastatic Cancer","Squamous Cell Carcinoma of Head and Neck","Non Small Cell Lung Cancer","Small-cell Lung Cancer","Bladder Cancer","Endometrial Cancer","Castration Resistant Prostatic Cancer","Cervical Cancer","Colorectal Cancer","Gastric Cancer","Gastro-esophageal Cancer","Pancreas Cancer","Clear Cell Renal Cell Carcinoma","Hepatocellular Carcinoma","Platinum-resistant Ovarian Cancer","Breast Cancer","Ovarian Cancer","Esophageal Squamous Cell Cancer (SCC)","2026-08-10",{"date":83,"type":32},{"date":128,"type":32},"2024-03-06",{"date":130,"type":19},"2028-10",{"name":132,"class":133},"MacroGenics","INDUSTRY",12,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":16,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":50,"phases":146,"briefSummary":147,"conditions":148,"keywords":152,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":40},"100239104","phase-1-phase-i-trial-of-turalior-pexidartinib-plx3397-in-children-and-young-adults-with-refractory-leukemias-and-refractory-solid-tumors-including-neurofibromatosis-type-1-nf1-associated-plexiform-neurofibromas-pn-and-tenosynovial-giant-cell-tumor--100239104","NCT02390752","Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...","Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)","* INCLUSION CRITERIA:\n* Diagnosis:\n\n  * Individuals must have recurrent or refractory solid tumors or acute leukemia (limited to AML or ALL) or have been intolerant of prior therapies, confirmed by the Laboratory of Pathology, NCI, e.g., solid tumors including rhabdomyosarcoma, Ewing sarcoma, soft tissue sarcomas. These may include primary neoplasms of the central nervous system, such as high-grade (WHO grade III-IV) glioma. Individuals with diffuse intrinsic pontine glioma (DIPG) or optic pathway glioma are exempt from histologic verification. For DIPG typical MRI findings must be present which include hypo- or isointense on T1-weighted imaging, hyperintense on FLAIR or T2-weighted imaging, epicenter in the pons in the face of a typical clinical presentation. Optic pathway gliomas are located in the optic pathway and are typically hypo- or iso-intense on T1 and hyperintense on T2-weighted images.\n  * In addition, individuals with NF1 and with malignant peripheral nerve sheath tumor (MPNST).\n\n    * Individuals must have relapsed after or be refractory to effective standard therapies. There are no limits on number of prior therapeutic regimens.\n* Disease status: Individuals with refractory solid tumors including patients with NF1 and MPNST must have evaluable disease, patients with leukemia must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry.\n* Age \\>= 3 and \\\u003C= 35 years of age (must have BSA \\>= 0.55 m\\^2):\n* Ability of subject or Legally Authorized Representative \\[LAR\\] (the parent\u002Fguardian if subject is a minor) to understand and the willingness to sign a written informed consent document.\n* Individuals must be able to swallow capsules.\n* Performance Status: Karnofsky \\>= 50% for patients \\> 16 years of age and Lansky \\>= 50% for patients \\\u003C= 16 years of age. Individuals who are wheelchair bound because of paralysis will be considered \"ambulatory\" when they are up in their wheelchair. Individuals have to be able to travel to the NIH for evaluations.\n* Prior therapy:\n\nIndividuals must have fully recovered (to Grade 1) from the acute toxic effects of all prior anti-cancer therapy.\n\n* Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).\n* Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.\n* Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.\n* Monoclonal antibodies: At least 3 half-lives of the antibody after the last dose of a monoclonal antibody.\n* XRT: At least 7 days after local palliative XRT (small port); At least 150 days must have elapsed if prior TBI or if \\>= 50% radiation of pelvis; \\>= 14 days from whole brain radiation, craniospinal radiation, or targeted radiation to CNS tumors. At least 42 days must have elapsed if other substantial BM radiation.\n* HSCT: \\>= 56 days from stem cell transplant with no evidence of active graft vs. host disease; must be off immunosuppressive therapy for at least 4 weeks and have no active graft-versus-host disease (GVHD) at the time of entry onto this trial.\n* Surgery: \\>= 14 days from surgery\n* Others: \\>= 7 days from last dose of short active hematopoietic growth factors, i.e. filgrastim, \\>= 14 days for long-acting, i.e. pegfilgrastim.\n* Steroids: Individuals with CNS tumors who are managed with steroids are eligible if they have no worsening neurologic deficits and are on a stable or decreasing dose of corticosteroids for greater than or equal to 7 days prior to registration. Individuals with leukemia receiving corticosteroids or hydroxyurea are eligible provided that the corticosteroids are not being used to manage GVHD and there has been no increase in corticosteroid of hydroxyurea dose for 7 days prior to starting TURALIO(R).\n\n  -Individual must have adequate hematologic, hepatic, and renal function, defined by:\n* Absolute neutrophil count \\>= 1.5 x 10\\^9\u002FL\n* Hemoglobin \\> 10 g\u002FdL\n* Platelet count \\>= 100 x 10\\^9\u002FL\n* AST and ALT \\\u003C= upper limit of normal (ULN)\n* TBil and DBil \\\u003C= ULN with an exception of patients with confirmed Gilbert's syndrome. For patients with confirmed Gilberts syndrome, the TBil should be \\\u003C= 1.5 x ULN\n* Serum creatinine \\\u003C= 1.5 x ULN\n* Exceptions:\n\n  * Cytopenias due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy); A subject will not be excluded because of cytopenia due to disease, based on the results of bone marrow studies.\n  * Known active or chronic human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection, or positive hepatitis B (Hep B) surface antigen. Prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection and with normal liver function (ALT, AST, total and direct bilirubin \\\u003C= ULN) is allowed.\n  * Hepatobiliary diseases including biliary tract diseases, autoimmune hepatitis, inflammation, fibrosis, cirrhosis of liver caused by viral, alcohol, or genetic reasons. Gilbert's disease is allowed if TBil is \\\u003C= 1.5 x ULN.\n\n    * Cardiac ejection fraction \\>= 50%, and QTcF \\\u003C 450 ms (male) or \\\u003C470 ms (female) on ECG at Baseline. (Fridericia's Formula: QTcF = (QT)\u002FRR0.33)\n    * Contraception: Women of child-bearing potential must agree to use an effective method of birth control during treatment and for 1 month after receiving their last dose of study drug. Fertile men must also agree to use an acceptable method of birth control while on study drug and for at least one month after last dose.\n\nEXCLUSION CRITERIA:\n\n* Individuals who are pregnant or breast feeding or who become pregnant while enrolled on this trial will be excluded from participation, due to the unknown effects of TURALIO(R) on a growing fetus or newborn child.\n* Ongoing treatment with any other cancer therapy or investigational agent, with the exception of IT chemotherapy for leukemia, when indicated.\n* Individuals who require therapy with warfarin.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Active untreated infection.\n* Known active hepatitis A, B, C or HIV infection, chronic Hepatitis B or C, or HIV infection or inactive Hepatitis B carrier.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to TURALIO(R) or other agents used in study.\n* Individuals with PT and\u002For INR higher than or equal to 1.5 times upper limit of normal, unless patients have lupus anticoagulant in which case they are eligible if cleared by hematology.\n* Drugs that strongly inhibit or potentiate CYP3A4, which includes CYP3A4 inducer, UGT inhibitors and acid reducing agents and avoid concomitant use of PPIs:\n\n  * Individuals who have received these drugs within 14 days or within 5 half-lives of the drug (whichever is longer) prior to study initiation will be excluded.","3 Years","35 Years",{"count":145,"type":19},54,[75],"Background:\n\n\\- Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.\n\nObjectives:\n\n\\- To find the highest safe dose and side effects of TURALIO(R). To see if it helps treat certain types of cancer.\n\nEligibility:\n\n\\- People ages 3-35 with a solid tumor or leukemia that has returned or not responded to cancer therapies.\n\nDesign:\n\n* Individuals will be screened with:\n* Medical history\n* Physical exam\n* Blood and urine tests\n* Heart tests\n* Scans or other tests of the tumor\n* Individuals will take TURALIO(R) as a capsule once daily for a 28-day cycle. They can do this for up to 2 years.\n* During the study, participants will have many tests and procedures. They include repeats of the screening tests. Individuals will keep a diary of symptoms.\n* Individuals with solid tumors will have scans or x-rays.\n* Individuals with leukemia will have blood tests. They may have a bone marrow sample taken.\n* Some individuals may have a biopsy.\n* When finished taking TURALIO(R), individuals will have follow-up visits. They will repeat the screening tests and note side effects.",[149,150,151,27],"Neurofibroma, Plexiform","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Leukemia, Promyelocytic, Acute",[153,154,155,156],"Maximum Tolerated Dose","Dose Escalation","Acute Lymphocytic Leukemia","Acute Myelogenous Leukemia","2026-08-06",{"date":159,"type":32},"2026-08-07",{"date":161,"type":32},"2015-04-29",{"date":163,"type":19},"2028-12-31",{"name":165,"class":166},"National Cancer Institute (NCI)","NIH",{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":50,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":201},"100597545","distance-based-exercise-to-preserve-function-and-prevent-disability-100597545","NCT07059884","Distance-Based Exercise to Preserve Function and Prevent Disability","DEFEND","Inclusion Criteria:\n\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon\u002Frectum, endometrium, esophagus, gallbladder, head\u002Fneck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed)\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder:\n\n  \\* Providing clinical care for participating patients on this study\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English\n\nExclusion Criteria:\n\n\\-",{"count":175,"type":19},104,[52],"This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.",[179,180,181,122,114,182,112,183,184,116,185,186,187,188,123,189,190,191,27],"Localized Malignant Solid Neoplasm","Anal Cancer","Bladder (Urothelial, Transitional Cell) Cancer","Colon Cancer","Esophageal Cancer","Gall Bladder Cancer","Kidney Cancer","Liver Cancer","Lung Cancer","Head and Neck Cancer","Pancreatic Cancer","Prostate Cancer","Rectal Cancer","2026-08-04",{"date":194,"type":32},"2026-08-05",{"date":196,"type":32},"2026-02-11",{"date":198,"type":19},"2027-08-31",{"name":200,"class":39},"Alliance for Clinical Trials in Oncology",18,{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":209,"sex":16,"minAge":210,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":280},"100464928","collecting-blood-samples-from-patients-with-and-without-cancer-to-evaluate-tests-for-early-cancer-detection-100464928","NCT05334069","Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","Blinded Reference Set for Multicancer Early Detection Blood Tests","Inclusion Criteria:\n\n* Participants with a cancer diagnosis: Documentation of disease:\n\n  * Histologic documentation: Histologically confirmed diagnosis of invasive cancer\n  * Stage: Stage I-IV per American Joint Committee on Cancer (AJCC) 7th edition, with the exception of patients with leukemia, lymphoma, and multiple myeloma\n\n    * For leukemia: Type (chronic lymphocytic leukemia \\[CLL\\], chronic myeloid leukemia \\[CML\\], acute lymphoblastic lymphoma \\[ALL\\], acute myeloid leukemia \\[AML\\])\n    * For lymphoma: Stage I-IV based on Ann Arbor staging\n    * For multiple myeloma: Stage I, II, III based on Revised International Staging System (RISS)\n  * One of the following tumor types:\n\n    * Colorectal\n    * Bladder\n    * Head and neck\n    * Hepatobiliary\n    * Lung\n    * Lymphoma\n    * Leukemia\n    * Ovary \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Pancreas \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Multiple myeloma\n    * Gastric, esophageal or gastroesophageal\n    * Breast\n    * Thyroid\n    * Kidney\n\n      * For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Endometrium\n    * Prostate\n    * Melanoma\n\n      \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Sarcoma\n* Participants with a cancer diagnosis: No prior definitive systemic or local anti-cancer intervention\n* Participants with a cancer diagnosis: Age \\>= 40 and =\\\u003C 75\n* Participants with a cancer diagnosis: No known current pregnancy by self-report\n* Participants with a cancer diagnosis: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) other than the current cancer diagnosis\n* Participants with a cancer diagnosis: Willingness to provide blood samples for research use\n* Participants with a cancer diagnosis: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants with a cancer diagnosis: No history of organ transplantation\n* Participants with a cancer diagnosis: Ability to read and comprehend English or Spanish\n\n  \\* Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages\n* Participants without a cancer diagnosis and without suspicion of cancer: Age \\>= 40 and =\\\u003C 75\n* Participants without a cancer diagnosis and without suspicion of cancer: No known current pregnancy by self-report\n* Participants without a cancer diagnosis and without suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers)\n* Participants without a cancer diagnosis and without suspicion of cancer: Willingness to provide blood samples for research use\n* Participants without a cancer diagnosis and without suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants without a cancer diagnosis and without suspicion of cancer: No history of organ transplantation\n* Participants without a cancer diagnosis and without suspicion of cancer: Ability to read and comprehend English or Spanish\n\n  \\* Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages\n* Participants with a high suspicion of cancer: High suspicion of ovarian cancer, pancreatic cancer, kidney cancer, or melanoma by clinical and\u002For radiological assessment, with plans for histologic or cytologic confirmation within 28 days after study blood draw\n\n  \\* Examples of highly suspicious cases include: elevated CA125 and abnormal transvaginal ultrasound, suspicious renal or pancreatic mass on imaging, suspicious cutaneous lesion concerning for melanoma\n* Participants with a high suspicion of cancer: Central review of radiology reports and\u002For clinical documentation conducted by study chairs\n* Participants with a high suspicion of cancer: Age \\>= 40 and =\\\u003C 75\n* Participants with a high suspicion of cancer: No known current pregnancy by self-report\n* Participants with a high suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) other than the current cancer diagnosis\n* Participants with a high suspicion of cancer: Willingness to provide blood samples for research use\n* Participants with a high suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants with a high suspicion of cancer: No history or organ transplantation\n* Participants with a high suspicion of cancer: Ability to read and comprehend English or Spanish \\* Eligibility is restricted to individuals who can comprehend and read English and Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages",true,"40 Years","75 Years",{"count":213,"type":19},2000,"This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.",[216,217,218,219,220,221,222,223,224,225,24,226,227,228,25,26,229,230,231,232,27,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Ann Arbor Stage I Lymphoma","Ann Arbor Stage II Lymphoma","Ann Arbor Stage III Lymphoma","Ann Arbor Stage IV Lymphoma","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia","Gastroesophageal Junction Adenocarcinoma","Head and Neck Carcinoma","Invasive Breast Carcinoma","Kidney Carcinoma","Malignant Hepatobiliary Neoplasm","Muscle-Invasive Bladder Carcinoma","RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma","RISS Stage III Plasma Cell Myeloma","Stage I Bladder Cancer AJCC v6 and v7","Stage I Breast Cancer AJCC v7","Stage I Colorectal Cancer AJCC v6 and v7","Stage I Esophageal Cancer AJCC V7","Stage I Gastric Cancer AJCC V7","Stage I Lung Cancer AJCC v7","Stage I Ovarian Cancer AJCC v6 and v7","Stage I Pancreatic Cancer AJCC v6 and v7","Stage I Prostate Cancer AJCC v7","Stage I Uterine Corpus Cancer AJCC v7","Stage II Bladder Cancer AJCC v6 and v7","Stage II Breast Cancer AJCC v6 and v7","Stage II Colorectal Cancer AJCC v7","Stage II Esophageal Cancer AJCC v7","Stage II Gastric Cancer AJCC v7","Stage II Lung Cancer AJCC v7","Stage II Ovarian Cancer AJCC v6 and v7","Stage II Pancreatic Cancer AJCC v6 and v7","Stage II Prostate Cancer AJCC v7","Stage II Uterine Corpus Cancer AJCC v7","Stage III Bladder Cancer AJCC v6 and v7","Stage III Breast Cancer AJCC v7","Stage III Colorectal Cancer AJCC v7","Stage III Esophageal Cancer AJCC v7","Stage III Gastric Cancer AJCC v7","Stage III Lung Cancer AJCC v7","Stage III Ovarian Cancer AJCC v6 and v7","Stage III Pancreatic Cancer AJCC v6 and v7","Stage III Prostate Cancer AJCC v7","Stage III Uterine Corpus Cancer AJCC v7","Stage IV Bladder Cancer AJCC v7","Stage IV Breast Cancer AJCC v6 and v7","Stage IV Colorectal Cancer AJCC v7","Stage IV Esophageal Cancer AJCC v7","Stage IV Gastric Cancer AJCC v7","Stage IV Lung Cancer AJCC v7","Stage IV Ovarian Cancer AJCC v6 and v7","Stage IV Pancreatic Cancer AJCC v6 and v7","Stage IV Prostate Cancer AJCC v7","Stage IV Uterine Corpus Cancer AJCC v7","Thyroid Gland Carcinoma",{"date":194,"type":32},{"date":276,"type":32},"2022-08-18",{"date":278,"type":19},"2027-02-28",{"name":200,"class":39},744,{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":16,"minAge":288,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":50,"phases":291,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":305},"100650786","phase-1-multi-modular-chimeric-antigen-receptor-t-cells-targeting-b7-h3-in-children-teenage--young-adult-sarcoma-100650786","NCT07751380","Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma","MIGHTY","Inclusion Criteria:\n\n1. Age ≥ 1 and ≤ 24 years.\n2. Tissue diagnosis of RMS, ES or DSRCT\n3. Expression of B7-H3 in the tumour\n4. Relapsed or refractory disease after one or multiple lines of previous treatment.\n5. Measurable disease by cross sectional imaging. Patients with only bone marrow detectable disease (bone marrow aspirate or trephine) are NOT eligible for the study.\n6. At least 3 weeks or 5 half-lives, whichever is shorter, after treatment with agents on other early phase clinical trial.\n7. Performance status: Karnofsky (age ≥ 10 years) or Lansky (age \\\u003C 10) score ≥ 50%.\n8. Creatinine ≤1.5 x Upper Limit of Normal (ULN) for age, if higher, an estimated (calculated) creatinine clearance must be ≥ 60 ml\u002Fmin\u002F1.73 m2.\n9. Left ventricular ejection fraction (LVEF) ≥ 50%\n10. Absolute lymphocyte count ≥ 0.25 x 109\u002FL.\n11. Women of childbearing potential (WOCBP) must have a negative pregnancy test and agree to comply with the pregnancy reporting requirements of the protocol (if applicable).\n12. Written informed consent.\n\nExclusion Criteria:\n\n1. Patients with only bone marrow detectable disease in the absence of measurable disease by cross sectional imaging.\n2. Patients with active, inoperative central nervous system (CNS) disease including leptomeningeal disease.\n3. Active hepatitis B, C or HIV infection.\n4. Inability to tolerate leukapheresis.\n5. Clinically significant systemic illness or medical condition (e.g., significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the judgement of the investigator is likely to interfere with assessment of safety or efficacy of the investigational regimen and its requirements.\n6. Any contraindication to lymphodepletion or to the use of Cyclophosphamide or Fludarabine as per the local SmPC.\n7. Any contraindication to the use of Anticoagulant Citrate Dextrose Solution.\n8. Known allergy to albumin, EDTA or DMSO.\n9. Primary immunodeficiency or history of autoimmune disease (e.g., Crohn's, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression \u002Fsystemic disease modifying agents within the last 2 years.\n10. Prior treatment with investigational or approved gene therapy or cell therapy products.\n11. Life expectancy \\\u003C3 months.\n12. Systemic corticosteroid therapy ≥ 0.05 mg\u002Fkg dexamethasone daily (or equivalent) at time of hBRCA84D CAR T cells infusion.\n13. Women who are pregnant or breastfeeding.\n14. Patients who have received any live vaccine in the six weeks prior to planned lymphodepletion\n\nExclusion criteria for the ATIMP infusion:\n\n1. Uncontrolled fungal, bacterial, viral, or other infection. Previously diagnosed infection for which the patient continues to receive antimicrobial therapy is permitted if responding to treatment and clinically stable at the time of scheduled hBRCA84D CAR T cell infusion.\n2. Systemic corticosteroid therapy ≥ 0.05 mg\u002Fkg dexamethasone daily (or equivalent) at time of hBRCA84D CAR T cell infusion.","1 Year","24 Years",{"count":134,"type":19},[75],"MIGHTY is a multicentre, open label, phase 1 clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children, teenagers and young adults aged 1-24 with relapsed or refractory (r\u002Fr) rhabdomyosarcoma (RMS), Ewing sarcoma (ES) or desmoplastic small round cell tumour (DSRCT).\n\nThe study will assess the feasibility of generating the ATIMP and administering hBRCA84D CAR T cells to patients with r\u002Fr RMS, ES or DSRCT.",[27],[295,296],"sarcoma","CAR T cells","2026-08-03",{"date":159,"type":32},{"date":300,"type":32},"2025-07-23",{"date":302,"type":19},"2042-07",{"name":304,"class":39},"University College, London",2,{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":50,"phases":315,"briefSummary":316,"conditions":317,"keywords":322,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":335},"100586075","phase-1-idov-immune-for-advanced-solid-tumors-100586075","NCT06910657","IDOV-Immune for Advanced Solid Tumors","A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors","Key Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed advanced solid tumors that have progressed despite standard therapy, or for which no standard therapy exists.\n* ECOG performance status ≤ 1.\n* Measurable disease per RECIST v1.1.\n* Adequate organ and bone marrow function.\n* At least 28 days since major surgery, prior immunotherapy, or radiotherapy (with exceptions for minor procedures).\n* Negative pregnancy test for women of childbearing potential.\n* Agreement to use effective contraception during treatment and for 3 months after.\n* Ability to provide informed consent and comply with study requirements.\n\nKey Exclusion Criteria:\n\n* Prior treatment with an oncolytic virus.\n* Active or recent vaccinia virus infection or smallpox\u002Fmonkeypox vaccination within 10 years.\n* Active uncontrolled infection requiring systemic treatment.\n* History of hepatitis B, hepatitis C, or HIV (unless meeting protocol-specific criteria).\n* Unresolved ≥ Grade 2 toxicities from prior therapies (except hair loss or stable chronic conditions).\n* Active or symptomatic autoimmune disease requiring systemic therapy.\n* Active or untreated CNS metastases (unless stable per protocol).\n* Significant cardiac disease (e.g., NYHA Class III\u002FIV heart failure).\n* Interstitial lung disease or prior pneumonitis requiring steroids.\n* Conditions requiring chronic immunosuppressive therapy.\n* Severe skin disorders or history of pancreatitis.\n* Bleeding disorders or history of recent serious thromboembolic events.\n* Any medical or psychiatric condition that could interfere with study participation.",{"count":314,"type":19},78,[75],"This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor.\n\nThe purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors.\n\nParticipants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer.\n\nThis study is being conducted at multiple sites in the United States and Australia.",[115,189,26,123,116,183,120,318,122,27,111,187,190,319,320,321],"Renal Cell Carcinoma","Cervical Cancers","Head and Neck Cancers","Adrenal Gland Tumors",[323,324,107,325,326,327],"Oncolytic Virus Therapy","Advanced Solid Tumors","Refractory Cancer","Immunotherapy","Vaccinia Virus",{"date":194,"type":32},{"date":330,"type":32},"2025-08-25",{"date":332,"type":19},"2027-05-31",{"name":334,"class":133},"ViroMissile, Inc.",5,{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":209,"sex":16,"minAge":342,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":345,"conditions":346,"keywords":351,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":4,"leadSponsor":364,"locationsCount":335},"100141241","comprehensive-omics-analysis-of-pediatric-and-adult-solid-tumors-and-establishment-of-a-repository-for-related-biological-studies-100141241","NCT01109394","Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies","* SUBJECT INCLUSION CRITERIA:\n\nPediatric or adult subjects with one of the following:\n\n* Diagnosis of any tumor, malignancy, pre-malignant disorder, or suspected premalignant familial syndromes, regardless, of patient age;\n* Biological relatives of any patient with a tumor, malignancy, pre-malignant disorder, or suspected familial pre-malignant syndrome, regardless of patient age or the diagnosis of an adult malignancy or pre-malignant disorder;\n* Healthy Volunteer without history of malignancy nor a family member currently being treated for cancer who are undergoing surgery, treatment or during well visits;\n* Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care.\n* Human samples, specimens and data collected on IRB approved protocols that are now closed\n* Ability of subject, Legally Authorized Representative (LAR), or parent\u002Flegal guardian of children \\\u003C=18 to understand and be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects.\n\nInclusion Criteria for Social and Behavioral Outcome Interviews:\n\n* Parent\u002Fcaregiver of a participating pediatric or adult patient who is being treated for, or who has previously been treated for any form of pediatric cancer.\n* Must be able to give consent and sign the informed consent document.\n* Able to understand the English language.\n\nEXCLUSION CRITERIA:\n\nNone","4 Weeks",{"count":344,"type":19},6035,"Background:\n\n\\- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childhood cancers such as leukemia and tumors of the central nervous system.\n\nObjectives:\n\n\\- To collect and store blood, serum, tissue, urine, or tumor samples of children who have cancer or adults who have common childhood cancers.\n\nEligibility:\n\n* Individuals who have been diagnosed with a common childhood cancer (e.g., leukemia) regardless of patient age.\n* Children, adolescents, and adults who have been diagnosed with a type of cancer more commonly found in adults.\n\nDesign:\n\n* Extra blood, serum (the liquid part of blood), tissue, urine, or tumor samples will be collected from participants at a time when sampling is required for medical care or as part of a research study.\n* No additional procedures will be performed for the sole purpose of obtaining additional tumor tissue, aside from what is required for clinical care.",[27,347,348,349,350],"Endocrine Tumors","Neuroblastoma","Retinoblastoma","Renal Cancer",[352,353,354,355,356,357,358,359,27,185,348],"Genomics","Proteomics","Tissue Repository","Omics","Cell Lines","Natural History","Pediatric Cancer","Solid Tumor","2026-08-01",{"date":192,"type":32},{"date":363,"type":32},"2010-04-21",{"name":165,"class":166},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":16,"minAge":373,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":50,"phases":377,"briefSummary":379,"conditions":380,"keywords":385,"overallStatus":398,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":4},"100649901","phase-2-a-study-of-lifileucel-tumor-infiltrating-lymphocytes-in-adults-with-advanced-soft-tissue-sarcoma-100649901","NCT07741877","A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma","A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Soft Tissue Sarcoma","'SARATOGA'","Inclusion Criteria:\n\n* Participant must be ≥ 16 years of age at the time of signing the informed consent and assent.\n* Participants who are \\> 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.\n* Participant must have a confirmed diagnosis of histologically confirmed unresectable or metastatic UPS (Cohort 1) or DDLPS (Cohort 2), with or without a well-differentiated component, who have received ≥ 1 and a maximum of 3 prior systemic therapies, including ≥ 1 anthracycline-based regimen.\n* Participant has demonstrated progressive disease on or after the last line of therapy.\n* Participant is assessed as having at least one resectable lesion (or aggregate lesions) with an estimated minimum diameter of 1.5 cm (short axis) for lifileucel generation.\n* Following tumor resection for lifileucel generation, the participant will have at least one measurable lesion, as defined by RECIST v1.1 at Baseline.\n* Participant is expected to achieve washout from investigational or anticancer therapy(ies).\n* If the participant has preplanned surgical procedure(s), the procedure will take place at least 14 days (for major operative procedures) prior to the tumor resection. Wound healing will have occurred, and all complications will have resolved at the time of tumor resection.\n* Participant has recovered from all prior anticancer treatment-related AEs to Grade ≤ 1(per NCI-CTCAE), except for peripheral neuropathy, alopecia, or vitiligo.\n* Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.\n* Participants must have adequate organ function.\n* Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.\n\nExclusion Criteria:\n\n* Participant has symptomatic untreated brain metastases.\n* The participant has an ECOG performance status of ≥ 2, a need for urgent therapy due to rapidly progressive disease or tumor mass effect, or an estimated life expectancy of\\\u003C 6 months.\n* Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation.\n* Participant has any form of primary immunodeficiency (eg, severe combined immunodeficiency disease \\[SCID\\] or AIDS).\n* Participant has a history of hypersensitivity to any component of the study intervention.\n* Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or have been curatively treated \\> 1 year ago, and in the judgment of the investigator does not pose a significant risk of recurrence.\n\nOther protocol defined inclusion\u002Fexclusion criteria could apply.","16 Years","70 Years",{"count":376,"type":19},80,[378],"PHASE2","A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced soft tissue sarcoma ('SARATOGA')",[27,381,382,383,384],"Soft Tissue Sarcoma (STS)","Advanced Soft Tissue Sarcoma","Undifferentiated Pleomorphic Sarcoma (UPS)","Dedifferentiated Liposarcoma (DDLPS)",[386,387,388,389,390,391,27,392,382,393,394,395,396,397],"TIL","Tumor Infiltrating Lymphocytes","Cell Therapy","Cellular Immuno-therapy","IL2","Lifileucel","Soft Tissue Sarcoma","LN-145","Non-myeloablative lymphodepletion (NMALD)","SARATOGA","Undifferentiated pleomorphic sarcoma (UPS)","Dedifferentiated liposarcoma (DDLPS)","NOT_YET_RECRUITING","2026-07-30",{"date":297,"type":32},{"date":402,"type":19},"2026-09-01",{"date":404,"type":19},"2034-09-01",{"name":406,"class":133},"Iovance Biotherapeutics, Inc.",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":415,"conditions":416,"keywords":417,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":92},"100101177","novel-biochemical-and-molecular-determinants-for-soft-tissue-sarcoma-100101177","NCT00579566","Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma","Inclusion Criteria:\n\n* All patients with known or suspected sarcoma who will have or have had tissue removed for therapeutic or diagnostic purposes.\n* Patients will be entered without preference for any particular racial\u002Fethnic group or gender.\n* Patients may have received prior hormonal therapy, cytotoxic chemotherapy, irradiation, immunotherapy or surgical therapy.\n* Tissue specimens must be large enough in quantity to allow routine pathologic analysis, with the research laboratory specimen removed from the residual specimen, which would otherwise be discarded. Optimal tissue amounts for snap freeze: Core biopsy - 2 tissue cores Incisional biopsy- 0.5 to 1.5 grams Resected sarcoma specimen- 1.0 to 50 grams depending on size of specimen Normal fat or muscle tissue - 0.5 to 4.0 grams (if available from resected sarcoma specimen) Optimal tissue amounts for RNA later Core biopsy - 2 tissue cores Incisional biopsy- 30 mg (three 3 x 3 x 3 mm cubes) Resected sarcoma specimen - 30 mg (three 3 x 3 x 3 mm cubes) Normal fat or muscle tissue - 30 mg (three 3 x 3 x 3 mm cube\n\nExclusion Criteria:\n\n\\- None",{"count":414,"type":19},3000,"The purpose of this study is to study normal and sarcoma cells. To study these cells we need to have human tissue. You will be having or have already had a procedure to remove tissue. We would like to use some of this tissue. We will use it for laboratory studies on the diagnosis,behavior and treatment of sarcoma. We will perform an extensive analysis of your samples. We will only use extra tissue left over after all needed testing has been done or remove an additional small amount of tissue if you are having a biopsy. We will also take blood samples before and\u002For after your procedure to measure biochemical factors that may help us predict the behavior of sarcoma.",[27],[418,419],"Biochemical Determinants","Molecular Determinants","2026-07-29",{"date":399,"type":32},{"date":423,"type":32},"2002-06",{"date":425,"type":19},"2027-06",{"name":91,"class":39},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":50,"phases":436,"briefSummary":437,"conditions":438,"keywords":439,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":92},"100599861","phase-2-a-study-of-pembrolizumab-in-people-with-ultra-rare-sarcomas-100599861","NCT07089992","A Study of Pembrolizumab in People With Ultra-Rare Sarcomas","URSa-1: A Minibasket Study of Pembrolizumab in Ultra-Rare Sarcomas","Inclusion:\n\n* Patients must have pathologically confirmed diagnosis of one of the following:\n\n  1. Pleomorphic liposarcoma\n  2. PEComa (perivascular epithelial cell tumor)\n  3. Epithelioid sarcoma\n  4. CIC-rearranged sarcoma\n  5. SEF\u002FLGFMS: Sclerosing epithelioid fibrosarcoma - low grade fibromyxoid sarcoma\n* Molecular characterization of the tumor, if available, will be recorded. If no such molecular data are available, note as such.\n* Patient should have recurrent or metastatic disease not judged to be curable with other means\n* Patients must have progressed (in the opinion of the treating investigator) following the most recent line of therapy or stop prior therapy due to toxicity or patient choice. The reason for this progression or other reason for changing therapy must be documented, employing tumor measurements when available.\n* Definition of Measurable Disease\n\n  * Measurable disease as per RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions for a minimum of 3 months after completion of such therapy\n  * Patients with treated brain metastases are eligible if follow up brain imaging after CNS-directed therapy shows no evidence of progression at least 4 weeks after the completion of therapy as shown by follow up imaging before study screening\n  * One to 3 prior lines of therapy are permitted (including neoadjuvant\u002Fadjuvant or metastatic\u002Frecurrent disease)\n  * Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible. Patients with alopecia and other toxicities considered clinically nonsignificant and\u002For stable on supportive therapy, as determined by the investigator, are also permitted on study.\n  * Administration of killed vaccines is allowed\n* Age ≥ 18 years of age.\n* ECOG Performance Status 0-1 (Karnofsky 70-100)\n* Required organ function (specimens to be collected within 14 days of the start of the study intervention)\n\n  * Adequate hematologic function, defined as:\n\n    * Absolute neutrophil count (ANC) ≥ 1,000 cells\u002Fmm\\^3\n    * Platelets ≥ 100,000 cells\u002Fmm\\^3\n    * Hemoglobin ≥ 9 g\u002Fdl\n  * Adequate renal function defined, as:\n\n    * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert disease who have bilirubin level ≤ 3 x ULN may be enrolled)\n    * AST and ALT ≤3 x institutional ULN\n  * Adequate cardiac function, defined as: class II or better New York Heart Association (NYHA) Functional Classification.\n  * For patients with known HIV, HBV, and\u002For HCV infection \\[HIV, HBV, and HCV testing do not need to be performed as part of the study; the below language provides guidelines for inclusivity of patients with known HIV, HBV, and\u002For HCV infection\\]:\n\n    * HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and CD4+ T cell count of at least 350 cell\u002Fmm3 are eligible for this trial.\n    * HIV-infected patients with a history of either Kaposi sarcoma or Castleman disease are excluded from this study\n    * HIV-infected patients must not have had an AIDS defining opportunistic infection within the past 12 months\n  * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n  * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n\nExclusion:\n\n* No prior diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior to the first dose of study drug.\n* No other active malignancy, other than breast or prostate cancer stable for at least 6 months on hormonal therapy, or CLL Rai stage 0. Cancer in situ will not be considered an active malignancy.\n* No active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid)\n* No prior (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n* Must have adequately recovered from major surgery (at least 4 weeks), without ongoing surgical complications. Patients should have had any minor procedures (e.g. port placement, percutaneous nephrostomy) at least 2 weeks prior to the first day of treatment.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's ability to cooperate with the requirements of the study participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n* No known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Not pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n* No prior allogenic tissue\u002Fsolid organ transplant.\n* Patients with documented leptomeningeal disease are excluded from study, even if treated.\n* No prior systemic anti-cancer therapy including investigational agents within 4 weeks, 2 weeks for kinase inhibitors or intravenous chemotherapy, prior to starting therapy on study\n* No investigational agent(s) administration or use of investigational device within 4 weeks prior to study intervention administration.\n* No prior radiotherapy within 2 weeks of start of study intervention or radiation-related toxicities requiring corticosteroids. Note: Two weeks or fewer of palliative radiotherapy for non-CNS disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention.\n* No prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).\n* No live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention.\n* No known bleeding diathesis (e.g. hemophilia, DIC)\n* No active infection requiring systemic therapy\n* No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent (s) (or any of its excipients).",{"count":435,"type":19},32,[378],"The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma. The researchers will also study how the immune system responds to the study treatment.\n\nPembrolizumab is a type of drug called a PD-1 inhibitor. It is designed to block a protein called programmed cell death protein 1 (PD-1) that usually acts as a \"brake\" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.",[27],[440,441,442,443,444,445,446,447],"Pleomorphic liposarcoma","PEComa (perivascular epithelial cell tumor)","Epithelioid sarcoma","CIC-rearranged sarcoma","SEF\u002FLGFMS: Sclerosing epithelioid fibrosarcoma - low grade fibromyxoid sarcoma","Ultra-Rare Sarcomas","Pembrolizumab","25-165","2026-07-27",{"date":450,"type":32},"2026-07-28",{"date":452,"type":32},"2025-12-04",{"date":454,"type":19},"2028-12",{"name":91,"class":39},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":16,"minAge":463,"maxAge":210,"enrollmentInfo":464,"targetDuration":4,"studyType":50,"phases":466,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":479},"100648719","phase-1-domatinostat-with-sirolimus-for-relapsed-refractory-sarcoma-and-osteosarcoma-100648719","NCT07725380","Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma","Open-Label, Cohort-Sequential Dose-Escalation and Dose-Confirmation Phase 1\u002F2 Clinical Trial to Evaluate the Safety and Efficacy of Domatinostat in Combination With Sirolimus in Adolescents and Adults With Relapsed, Refractory Sarcoma and Osteosarcoma","Inclusion Criteria:\n\n* Age ≥12 and ≤40 years.\n* Histologically confirmed relapsed or refractory sarcoma (Phase 1) or osteosarcoma (Phase 2).\n* At least one prior standard systemic therapy regimen.\n* Not candidates for available therapies known to provide survival benefit.\n* Karnofsky\u002FLansky performance score ≥60.\n* Life expectancy ≥16 weeks.\n* Adequate organ function: ANC ≥1,000\u002FmcL, Platelets ≥100,000\u002FuL, Hemoglobin ≥8 g\u002FdL, Adequate hepatic and renal function.\n* Ability to swallow tablets.\n* Negative pregnancy test for females of childbearing potential.\n* Agreement to use effective contraception.\n* Ability to provide informed consent\u002Fassent.\n\nExclusion Criteria:\n\n* Receiving another investigational agent.\n* Receiving concurrent anticancer therapy.\n* Known hypersensitivity to domatinostat or sirolimus.\n* Bone marrow-only disease.\n* CNS metastatic disease.\n* Major surgery within 2 weeks prior to treatment.\n* Active malignancy within the previous 3 years (with protocol-specified exceptions).\n* History of solid organ transplantation.\n* Significant recent cardiac disease.\n* Concurrent prohibited CYP3A4\u002FP-gp interacting medications.\n* Uncontrolled infection or other serious uncontrolled illness.\n* Pregnancy or breastfeeding.\n* HIV infection on antiretroviral therapy.\n* Weight \\\u003C40 kg.\n* Inability to comply with study requirements.","12 Years",{"count":465,"type":19},74,[75,378],"This is a multicenter, open-label, Phase 1\u002F2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of domatinostat in combination with sirolimus in adolescents and adults with relapsed or refractory sarcoma and osteosarcoma.",[27,469],"Osteosarcoma","2026-07-21",{"date":472,"type":32},"2026-07-24",{"date":474,"type":32},"2026-07-15",{"date":476,"type":19},"2031-08",{"name":478,"class":39},"H. Lee Moffitt Cancer Center and Research Institute",4,{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":488,"enrollmentInfo":489,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":201},"100602476","destiny-pantumour04-100602476","NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","130 Years",{"count":490,"type":19},100,"This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[493,180,111,114,112,183,184,494,188,186,26,495,496,497,123,189,190,318,498,27,499,500,501,502,503,504,505],"Adenocarcinoma (NOS)","Gastrointestinal Stromal Tumour","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Salivary Gland Cancer","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer",{"date":507,"type":32},"2026-07-22",{"date":509,"type":32},"2025-09-18",{"date":511,"type":19},"2028-03-30",{"name":513,"class":133},"AstraZeneca",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":523,"conditions":524,"keywords":525,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":305},"100589722","lci-sar-bsts-ctdna-001-circulating-tumor-dna-liquid-biopsy-in-sarcoma-patients-100589722","NCT06958107","LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients","Prospective Clinical Evaluation of Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients","Inclusion Criteria:\n\n1. Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information.\n2. All ages allowed\n3. Suspected or confirmed disease (must meet one of the criteria below):\n\n   1. Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis)\n\n      OR\n   2. Suspected lipomatous mass concerning for ALT or WDLS with planned surgery\n\n      OR\n   3. Confirmed bone or soft tissue sarcoma meeting one of the criteria below:\n\n      * Non-metastatic\u002FResectable sarcoma with either planned or currently receiving therapy\n      * Metastatic or unresectable sarcoma, with planned or currently receiving therapy\n      * Non-metastatic sarcoma under surveillance with no more than 1 year from completion of therapy\n\nExclusion Criteria:\n\n* none",{"count":522,"type":19},300,"The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).",[27],[526,527,528],"circulating tumor DNA","liquid biopsy","bone or soft tissue Sarcoma",{"date":530,"type":32},"2026-07-23",{"date":532,"type":32},"2025-08-21",{"date":534,"type":19},"2030-01",{"name":536,"class":39},"Wake Forest University Health Sciences",{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":50,"phases":546,"briefSummary":547,"conditions":548,"keywords":549,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":40},"100521705","grid-therapy-for-extremity-soft-tissue-sarcoma-100521705","NCT06073067","GRID Therapy for Extremity Soft Tissue Sarcoma","Safety, Efficacy, and Mechanism of Pre-operative Spatially Fractionated GRID Radiation Therapy in Patients With Extremity Soft Tissue Sarcoma: A Pilot Study","In order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\nInclusion Criteria:\n\n1. Written informed consent was obtained to participate in the study and HIPAA authorization for the release of personal health information. Subjects are willing and able to comply with study procedures based on the judgment of the investigator.\n2. Age ≥ 18 years at the time of consent.\n3. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 2 (Karnofsky Performance Status equivalent of 50 - 100).\n4. Histological or cytological evidence\u002Fconfirmation of extremity soft tissue sarcoma as determined by core-needle biopsy or excision biopsy. If the diagnostic tissue is not available or sufficient to perform correlative studies, must be willing to provide the mandatory pre-treatment core-needle biopsy. In some cases of extremity STS, subjects undergo an attempted surgical resection for a presumed benign condition and the specimen reveals malignancy. Such subjects are allowed so long as a complete, oncologic, resection was not performed\u002Fattempted and there is ≥ 5 cm of the remaining primary tumor.\n\nExclusion Criteria:\n\nSubjects meeting any of the exclusion criteria listed below at baseline will be excluded from the study.\n\n1. Subjects who have received prior radiotherapy to the tumor site.\n2. Subjects who have undergone complete tumor resection of the primary tumor or who have developed tumor recurrence after resection.\n3. History of serious or non-healing wound, ulcer, or bone fracture in the treatment limb within the last 5 years.\n4. History of clinically significant lymphedema in the treated limb.\n5. History of lupus, scleroderma, Sjogren's syndrome, Ehlers-Danlos syndrome (any type), or other collagen vascular disease that may pose a relative contraindication, due to increased risk of skin or soft tissue toxicity, with radiation.",{"count":545,"type":19},20,[52],"Patients with extremity soft tissue sarcoma (STS) are at high risk of recurrence. Pre-operative radiotherapy is used to increase the safe removal of tumors and improve local control in these patients. Increasing the preoperative radiotherapy dose with standard techniques might lead to normal tissue toxicity and postoperative wound complications.\n\nGRID radiation therapy is a technique that may increases radiation dose with minimal added toxicity. It is hypothesized that GRID radiation dose will improve tumor response without increasing post-operative wound complications. While GRID has been used in many patients, there have been few formal studies to evaluate the safety and efficacy of the technique. In this study, a single priming dose of GRID will be administered to subjects with high-risk extremity soft tissue sarcoma prior to standard radiotherapy and tumor resection to determine the safety and clinical efficacy of the GRID dose. This single-arm pilot study will assess the safety of spatially fractionated grid radiation therapy (GRID) on 20 subjects with resectable extremity soft tissue sarcoma, followed by standard-of-care conventional radiotherapy (XRT) and tumor resection.",[27],[550,551,552,553,554],"extremity","radiation","GRID","surgery","preoperative",{"date":530,"type":32},{"date":557,"type":32},"2023-11-09",{"date":559,"type":19},"2027-11-10",{"name":561,"class":39},"UNC Lineberger Comprehensive Cancer Center",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":50,"phases":571,"briefSummary":572,"conditions":573,"keywords":576,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":590},"100591043","phase-1-stc-15-as-a-part-of-combination-therapy-with-toripalimab-in-selected-advanced-cancers-and-as-monotherapy-in-participants-with-selected-sarcomas-100591043","NCT06975293","STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas","Open-label, Non-randomized, Multi-cohort, Phase 1b\u002F2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas","Key Inclusion Criteria:\n\n* Estimated life expectancy ≥ 3 months.\n* ECOG performance status 0 or 1.\n* Measurable disease according to RECIST v1.1 as assessed by the local site investigator\u002Fradiology.\n* Documented radiologic assessment of progression on the prior therapy before study entry.\n* Have adequate organ function.\n* Have the ability to swallow, retain, and absorb oral medication.\n\nInclusion Criteria (Phase 2 Monotherapy Cohorts):\n\n* Have histologic or cytologic confirmation of advanced sarcoma of the selected histologic subtype that is not amenable to local curative therapy. Participant must have received at least 2, but no more than 4 prior lines of systemic therapy.\n* Pre-treatment and on-treatment biopsy if medically feasible.\n\nKey Exclusion Criteria:\n\n* Pregnant and lactating women.\n* Received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives, whichever is shorter, prior to first IMP administration.\n* Participants who have not recovered from all AEs due to previous therapies to Grade ≤ 1 or baseline, according to NCI-CTCAE v5.0. Exceptions include: alopecia, Grade ≤ 2 neuropathy, and endocrine-related AEs Grade ≤ 2 who are stable on treatment or hormone replacement.\n* History of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or the presence of ongoing pneumonitis\u002Finterstitial lung disease).\n* Clinically significant cardiovascular disease or condition.\n* Known active CNS metastases and\u002For leptomeningeal disease.",{"count":570,"type":19},107,[75,378],"This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \\[PD-1\\]) in advanced unresectable or metastatic tumors.\n\nThe Phase 2 Monotherapy part is an open-label, non-randomized, multicenter Simon's 2-stage design that investigates the safety, tolerability, and antitumor activity of STC-15 in participants with selected, relapsed sarcomas subtypes, dedifferentiated (DD) liposarcoma and leiomyosarcoma (uterine and non-uterine).",[359,27,574,575],"Leiomyosarcoma","Dedifferentiated Liposarcoma",[577,578,579,580],"STC-15","Toripalimab","PD1","Checkpoint Combination","2026-07-16",{"date":583,"type":32},"2026-07-20",{"date":585,"type":32},"2025-05-05",{"date":587,"type":19},"2028-06-29",{"name":589,"class":133},"STORM Therapeutics LTD",9,{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":50,"phases":599,"briefSummary":601,"conditions":602,"keywords":606,"overallStatus":398,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":40},"100622892","early-phase-1-immune-checkpoint-inhibitor-ici-drug-drug-interaction-ddi-study-100622892","NCT07389525","Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study","Assessment of Drug-Drug Interactions Between Immune Checkpoint Inhibitors and Cytochrome P450 Substrates: Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study","Inclusion Criteria:\n\n* ≥ 18 years old at the time of informed consent\n* Diagnosed with cancer AND initiating therapy with single agent or combination therapy that includes an immune checkpoint inhibitor (e.g., atezolizumab, cemiplimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatlimab, tremelimumab)\n* Ability to provide written informed consent and HIPAA authorization\n\nExclusion Criteria:\n\n* Actively pregnant or breastfeeding\n* Body weight less than 50 kg or a BMI \\>35\n* Low baseline hemoglobin, defined as \\\u003C10 g\u002FdL\n\n  * Note: if a prospective patient's hemoglobin returns to the normal range, they can be re-screened for trial inclusion)\n* Past medical history of chronic liver disease, signs and symptom of liver disease (e.g., jaundice, ascites), or aspartate aminotransferase \\>96 U\u002FL, alanine aminotransferase \\> 80 IU\u002FL, alkaline phosphatase \\>260 U\u002FL, or total bilirubin \\> 2.6 mg\u002FdL\n\n  * Note: if a prospective patient's liver function tests return to the normal ranges, they can be re-screened for trial inclusion)\n* Past medical history of chronic kidney disease, signs and symptom of kidney disease (e.g., decreased urine output, swelling in feet and ankles), or estimated glomerular filtration rate \\\u003C45 mL\u002Fminute\u002F1.73 m2 BSA\n\n  * Note: if a prospective patient's kidney function returns to the normal range, they can be re-screened for trial inclusion)\n* Poor performance status that makes it unlikely the patient will complete 3 cycles of immune checkpoint inhibitor (at the treating oncologist's discretion)\n* Diagnosis or past medical history of autoimmune disorder, including systemic lupus erythematosus, Crohn's disease, Sjogren's syndrome, multiple sclerosis, type 1 diabetes mellitus, Behcet's disease, and ankylosing spondylitis\n* History of intolerance, allergic reaction, or hypersensitivity to any of the study drugs (tizanidine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, rosuvastatin)\n* Current infection requiring medical treatment (note: if a prospective patient's infection resolves, they can be re-screened for trial inclusion)\n* Concomitant treatment with systemic immunosuppressant drugs (see Appendix 3 for list)\n\n  * Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1\n* Concomitant treatment with a CYP\u002Ftransporter probe cocktail drug or strong inhibitors, inducers, or agents that affect the pharmacokinetics of the relevant CYP enzymes or drug transporters (see Appendix 4 for list)\n\n  * Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1\n* Are unwilling\u002Funable to avoid drugs of abuse, tobacco products or marijuana, or consuming more than 2 alcoholic drinks per day during the study\n* Inability to take oral medication",{"count":376,"type":19},[600],"EARLY_PHASE1","Immune checkpoint inhibitors (ICIs) (also called \"immunotherapy\") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs work differently, or causing more side effects. The purpose of this study is to see whether ICIs impact how the liver processes other drugs. To do this, participants will be given a probe cocktail of 7 different FDA-approved drugs that are processed in different ways in the liver.",[603,604,605,27,26],"Gastrointestinal Neoplasms","Genitourinary Cancer","Thoracic Cancer",[607,608],"cytokines","immune checkpoint inhibitor","2026-07-14",{"date":474,"type":32},{"date":612,"type":19},"2026-09",{"date":614,"type":19},"2027-12",{"name":616,"class":39},"Indiana University",{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":16,"minAge":373,"maxAge":211,"enrollmentInfo":623,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":625,"conditions":626,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":40},"100305847","abductor-reattachment-methods-in-proximal-femur-replacements-what-is-the-best-method-100305847","NCT03261544","Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?","Inclusion Criteria:\n\n• Has undergone or is scheduled for proximal femur replacement by an Ortho Oncology surgeon\n\nExclusion Criteria:\n\n* Non-ambulatory before or after the procedure\n* Subjects who, in the opinion of the investigator, have not or likely will not complete at least some portion of the investigator's recommended follow-up",{"count":624,"type":19},50,"The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique. The investigators hypothesize that those patients who receive reattachment of the abductors directly into the prosthesis will have better functional outcomes overall. Furthermore, the investigators plan to develop a simple, cost effective, and reproducible method to assess abductor function at clinical post-operative visits through plain radiographs.",[27,627,628],"Bone Metastases","Proximal Femur Replacement",{"date":474,"type":32},{"date":631,"type":32},"2017-11-10",{"date":633,"type":19},"2028-11",{"name":635,"class":39},"Duke University",{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":50,"phases":645,"briefSummary":646,"conditions":647,"keywords":648,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":660},"100640082","phase-1-a-study-evaluating-the-efficacy-and-safety-of-risvutatug-rezetecan-in-participants-with-advanced-sarcomas-embold-sarcoma-202-100640082","NCT07602777","A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)","Phase 1b\u002F2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas","Inclusion Criteria:\n\n\\- Participants are eligible to be included in the study only if all of the following criteria apply\n\n* Participants must be ≥ 12 years of age.\n* Has histologically confirmed unresectable advanced or metastatic R\u002FR OSA (Cohort 1) or unresectable advanced or metastatic STS (Cohort 2) that has progressed to at least one prior line of systemic therapy.\n* Has documented disease progression on the last line of systemic treatment as confirmed by radiological imaging\n* Has an ECOG performance status of 0 or 1, or Lansky PS\u002FKarnofsky PS ≥ 70% for adolescent participants, with no deterioration in the 2 weeks prior to first dose\u002Frandomization.\n* Has adequate organ function.\n* All participants, or their legal guardians, must provide signed informed consent and agree to follow the study protocol before starting any study activities\n\nExclusion Criteria:\n\n\\- Participants are excluded from the study if any of the following key exclusion criteria apply:\n\n* Has received any prior therapy with an Antibody-drug-conjugates (ADC) with a TOPO1-inhibitor payload.\n* Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.\n* Has severe, uncontrolled or active cardiovascular disorders.\n* Known active infectious diseases requiring systemic treatment or known Human immunodeficiency virus (HIV).\n* Has symptomatic brain metastases or untreated progression exclusively due to brain metastasis during or after the last treatment prior to screening, evidence of leptomeningeal\u002Fmeningeal\u002Fbrainstem metastasis or evidence of spinal cord metastases.\n* Has received treatment with an investigational agent within 4 weeks of the first dose of study intervention.\n* Is pregnant or breastfeeding.",{"count":644,"type":19},113,[75,378],"The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it, and how their bodies handle the drug (how its absorbed and broken down). This research is for adolescents and adults who have either: Osteosarcoma, which is a type of bone cancer, or Soft Tissue Sarcoma, which is a type of cancer that starts in soft body tissues (like muscle, fat, or nerves). In both cancer types the cancer must have already been treated, but has come back or spread, and cant be removed by surgery",[27],[649,650,651,27],"EMBOLD Sarcoma-202","Risvutatug Rezetecan","Ris-Rez","2026-07-13",{"date":474,"type":32},{"date":655,"type":32},"2026-06-22",{"date":657,"type":19},"2029-11-23",{"name":659,"class":133},"GlaxoSmithKline",6,{"id":662,"slug":663,"hasResults":12,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":4,"eligibilityCriteria":667,"healthyVolunteers":12,"sex":16,"minAge":668,"maxAge":4,"enrollmentInfo":669,"targetDuration":4,"studyType":50,"phases":671,"briefSummary":672,"conditions":673,"keywords":4,"overallStatus":398,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":305},"100638050","phase-2-comparison-of-the-effects-of-needle-biopsy-tract-resection-and-non-resection-on-recurrence-rate-in-patients-with-primary-extremity-sarcoma-100638050","NCT07575724","Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma","Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma: Study Protocol of a Randomized, Non-inferior Clinical Trial","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of primary bone or soft tissue sarcoma of the extremities (or highly suspected sarcoma);\n2. Candidate for limb-sparing surgery and capable of en-bloc resection;\n3. Age ≥ 5 years;\n4. ECOG performance status 0-2;\n5. Able to understand and sign informed consent.\n\nExclusion Criteria:\n\n1. Presence of distant metastasis (e.g., lung, bone, or other sites) or unresectable skip lesions;\n2. Patients deemed, based on preoperative multidisciplinary team (MDT) evaluation, unlikely to achieve adequate surgical margins and therefore only eligible for debulking or palliative surgery;\n3. Patients with inconclusive needle biopsy results requiring open biopsy for definitive diagnosis;\n4. Patients requiring amputation;\n5. Patients who have received prior treatment for the tumor at non-participating centers;\n6. Patients with an expected survival of less than 2 years;\n7. Patients in whom the biopsy tract completely lies within the planned tumor resection field;\n8. Patients who refuse to provide written informed consent.","5 Years",{"count":670,"type":19},3300,[378],"This randomized, non-inferiority clinical trial aims to evaluate whether non-resection of needle biopsy tract is non-inferior to routine biopsy tract resection in terms of local recurrence in patients with primary extremity musculoskeletal sarcoma undergoing en-bloc surgical treatment.\n\nBiopsy tract resection is traditionally recommended to reduce the risk of tumor seeding; however, its benefit in reducing recurrence has not been definitively demonstrated, particularly when core needle biopsy is widely used. Also, avoiding biopsy tract resection may preserve uninvolved tissue without compromising oncologic safety.\n\nThe primary objective of this study is to compare local recurrence rates between patients who undergo biopsy tract resection and those who do not. Secondary objectives include comparisons of surgical complications, functional outcomes, overall survival, and progression-free survival.",[674,27],"Primary","2026-07-12",{"date":609,"type":32},{"date":678,"type":19},"2026-12-01",{"date":680,"type":19},"2033-12-01",{"name":682,"class":39},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":684,"slug":685,"hasResults":12,"nctId":686,"briefTitle":687,"officialTitle":688,"acronym":4,"eligibilityCriteria":689,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":690,"targetDuration":4,"studyType":50,"phases":692,"briefSummary":693,"conditions":694,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":704,"lastUpdatePostDateStruct":705,"startDateStruct":706,"completionDateStruct":708,"leadSponsor":709,"locationsCount":40},"100560657","phase-2-repurposing-riluzole-for-cancer-related-cognitive-impairment-a-pilot-trial-100560657","NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial","Inclusion Criteria:\n\n1. Cohort-specific inclusion for male and female patients.\n\n   a. Cohort A (no prior cranial radiation) i. Diagnosed with one of the following:\n   * Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and\u002For other breast cancer interventions.\n   * Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years.\n   * Non-breast cancer patients exposed to other anticancer therapies within the past 3 years.\n\n     b. Cohort B (prior cranial radiation)\n   * Previously received radiotherapy or radiosurgery to the brain for benign, malignant, or metastatic tumors.\n   * Life expectancy \\> 6 months\n2. Washout from investigational and conventional interventions is up to the discretion of the investigator. Concurrent participation in another intervention is allowable if judged by the Principal Investigator that this would not be scientifically or medically incompatible with this study.\n3. ≥18 years of age\n4. Perceived by patient or investigator that cognitive function has worsened since receipt of cranial radiation or cancer treatment.\n5. Able to provide informed consent.\n6. Literacy in English, Chinese, Korean, Vietnamese, or Spanish, to complete the questionnaires.\n7. Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes.\n\n   * Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.\n\nExclusion Criteria:\n\n1. Cohort-specific exclusion for male and female patients:\n\n   1. Cohort A (no prior cranial radiation)\n\n      * History of or current presence of primary brain tumors or brain metastases.\n   2. Cohort B (prior cranial radiation)\n\n      * Diagnosed with high grade glioma.\n2. Unwilling to undergo neuropsychological assessments necessary for the study.\n3. Women who are breastfeeding, pregnant or are planning to get pregnant during the study period. Persons of child-bearing potential (POCBP) must have a negative pregnancy test at screening if there is suspicion of pregnancy.\n\n   a. Female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n4. History of suspected hypersensitivity to riluzole or to any of its excipients.\n5. Patients taking or planned to take medications\u002Fsubstances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.\n6. Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN)\n7. Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.",{"count":691,"type":19},75,[378],"This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.",[122,27,116,187,188,115,123,186,604,695,696,697,698,699,190,118,700,701,702,26,703,185],"Gynecologic Cancer","Urinary Bladder Cancer","Leukemia","Lymphoid Leukemia","Myeloma Multiple","Non-hodgkin Lymphoma","Hodgkin Lymphoma","Brain Cancer","Mycosis Fungoides","2026-07-11",{"date":609,"type":32},{"date":707,"type":32},"2024-12-02",{"date":614,"type":19},{"name":710,"class":39},"University of California, Irvine",{"id":712,"slug":713,"hasResults":12,"nctId":714,"briefTitle":715,"officialTitle":716,"acronym":4,"eligibilityCriteria":717,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":718,"enrollmentInfo":719,"targetDuration":4,"studyType":50,"phases":721,"briefSummary":722,"conditions":723,"keywords":726,"overallStatus":398,"whyStopped":4,"lastUpdateSubmitDate":728,"lastUpdatePostDateStruct":729,"startDateStruct":730,"completionDateStruct":732,"leadSponsor":734,"locationsCount":40},"100458708","phase-2-trial-of-selumetinib-and-bromodomain-inhibitor-with-durvalumab-for-sarcomas-100458708","NCT05253131","Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas","Phase 1\u002F2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors","Inclusion Criteria:\n\nInclusion Criteria AGE: ≥ 18 years of age Weight: \\>30 kg Life expectancy of at least 12 weeks\n\nPart A and B (Phase 1): Patients with histologically confirmed soft tissue or bone sarcoma of the following subtypes:\n\n* MFH\u002F undifferentiated pleomorphic sarcoma\n* Unclassified sarcoma\n* Rhabdomyosarcoma\n* Malignant peripheral nerve sheath tumor (MPNST)\n* Osteosarcoma\n* Ewing or Ewing-like sarcoma\n* Synovial sarcoma\n* Desmoplastic small round blue cell tumor (DSRCT)\n\nPatients must have progressed or demonstrated disease that is refractory to standard therapies.\n\nPatients for whom no standard of care treatments exist are eligible.\n\nPart C (Phase 2): Patients with progressive, relapsed, unresectable or metastatic NF associated MPNST.\n\nMEASURABLE DISEASE:\n\nPatients must have evaluable or measurable disease (Phase 1) and measurable disease by RECISTv1.1 (Phase 2).\n\n* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering on this study excluding chronic grade 1 toxicities and alopecia.\n* No limitation on the number of prior chemotherapy regimens that the patient may have received prior to study entry.\n* Myelosuppressive chemotherapy: The last dose of all myelosuppressive anticancer drugs must be at least 3 weeks (≥21 days) and 42 days if prior nitrosourea prior to study entry.\n* Immunotherapy: The last dose of immunotherapy (monoclonal antibody or vaccine) must be at least 4 weeks prior to study entry.\n* Biologic (anti-cancer agent): The last dose of all biologic agents for the treatment of the patient's cancer (such as retinoids or tyrosine kinase inhibitors) must be at least 7 days prior to study entry. Prior therapy with a MEK, Ras, or Raf inhibitor used for treatment of malignant sarcoma is not allowed. Prior therapy of MEK, Ras, or Raf inhibitor for other tumor such as plexiform neurofibroma or glioma is allowed.\n* Radiation therapy: The last dose of radiation to more than 25% of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study\n* Radiation therapy: The last dose of radiation to more than 25% of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study entry. The last dose of all other local palliative (limited port) radiation must be at least 2 weeks prior to study entry.\n* Stem Cell Transplantation. At least 2 months post-autologous stem cell transplant.\n* Growth Factors. The last dose of colony stimulating factors, such as filgrastim, sargramostim, and erythropoietin, must be at least 1 week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be at least 2 weeks prior to study entry.\n* Karnofsky performance level ≥ 50% (See Appendix II).\n* Patients who are unable to walk because of paralysis or motor weakness, but who are able to use a wheelchair will be considered ambulatory for the purpose of calculating the performance score.\n\nHemoglobin ≥9.0 g\u002FdL (transfusion permissible)\n\n* Peripheral absolute neutrophil count (ANC) of ≥1000\u002FµL\n* Platelet count ≥100,000\u002FµL (transfusion independent (no transfusion within at least 7 days prior to enrollment))\n* Total bilirubin must be ≤ 1.5 times the upper limit of normal (ULN)\n* SGOT (AST)\u002FSGPT (ALT) must be ≤ 3.0 times ULN unless liver metastases are present, in which case it must be ≤ 5x ULN\n\nRENAL FUNCTION:\n\nSerum creatinine ≤ 1.5 times ULN or measured reatinine clearance \\>50 mL\u002Fmin or calculated creatinine clearance \\> 50 mL\u002Fmin by the Cockcroft- Gault formula (Cockgraft and Gault 1976) or by the 24 hour urine collection for determination of creatinine clearance\n\n* Normal ejection fraction (ECHO or cardiac MRI) ≥53% (or the institutional normal; if a range is given then the upper value of the range will be used)\n* QTC or QTcF ≤ 450msec\n\nFertile men and women of childbearing potential must agree to use an effective method of birth control.\n\nFemale participants of childbearing potential must be willing to practice highly effective contraception as detailed below from the time of screening until 3 months after discontinuing the study.\n\nThey must not be breastfeeding and must have negative pregnancy test prior to start of dosing.\n\nFor a female participant to be considered as of not childbearing potential, she should fulfil one of the following:\n\nPost-menopausal women, defined as either women aged more than 50 years and have amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments, or, women under 50 years who have amenorrhea for at least 12 months following cessation of exogenous hormonal treatments, and have serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in the postmenopausal range for the institution.\n\nor\n\n* Have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy (but not tubal ligation)\n* Have medically confirmed, irreversible premature ovarian failure.\n\nHighly effective methods of contraception are:\n\n* Use of medroxyprogesterone acetate depot injection (Depo-proveraTM). (Please note: use of any other oral, injected, or implanted hormonal methods of contraception cannot be considered highly effective as it is currently unknown whether investigational agents may reduce their effectiveness)\n* Placement of a copper-banded intrauterine device (IUD) or intrauterine system (IUS)\n* Bilateral tubal ligation\n* Vasectomized partner\n\nBarrier methods include:\n\nOcclusive cap (e.g. diaphragm or cervical\u002Fvault caps) with spermicide\n\nMale participants should either be surgically sterile or willing to use an effective barrier method of contraception during the study and for 3 months following the last dose of drug therapy if sexually active with a female of childbearing potential. If not done, storage of sperm prior to receiving drug therapy will be advised to male participants with a desire to have children.\n\nMale subjects must agree to refrain from sperm donation during and until 90 days from drug therapy discontinuation.\n\nCNS DISEASE: Patients with central nervous system disease are eligible or enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression or stable disease at 4 weeks.\n\nExclusion Criteria:History of another primary malignancy except for\n\n* A malignancy treated with curative intent and with no known active disease ≥5 years prior to study entry\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n* Adequately treated carcinoma in situ without evidence of disease\n* Stable optic pathway glioma or low grade glioma not receiving active therapy\n\nHistory of leptomeningeal carcinomatosis.\n\nPatients receiving other anti-cancer agents are not eligible.\n\nPatients who cannot swallow whole pills.\n\nHistory of allogeneic organ transplantation.\n\nCurrent or prior use of immunosuppressive medications within 14 days prior to study entry. The following are exceptions to this criterion:\n\nintranasal, inhaled, topical steroids or local steroid injection (e.g., intra-articular injection)\n\nSystemic corticosteroids used at physiologic doses not to exceed 10mg\u002Fday of prednisone or its equivalent.\n\nSteroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).\n\nPatients should not receive immunizations with attenuated live vaccines within four weeks of study entry or during study period.\n\nAny recent major surgery within a minimum of 4 weeks prior to starting drug therapy. Placement of vascular access device, percutaneous tumor biopsy, or bone marrows are not considered major surgical procedures and no minimum time frame prior to starting study drug.\n\nPatients who have any known severe and\u002For uncontrolled medical therapy is required.\n\nconditions or other conditions that could affect their participation in the study such as:\n\n* Severely impaired lung function defined as spirometry and DLCO that is 50%of the normal predicted value corrected for hemoglobin and alveolar volume and\u002For O2 saturation that is 88% or less at rest on room air. For patients who do NOT have respiratory symptoms (e.g., dyspnea at rest, known requirement for supplemental oxygen), pulmonary function test is not required.\n* Cardiac conditions as follows:\n\n  * Uncontrolled hypertension (blood pressure ≥150\u002F95 mmHg despite medical therapy.\n  * Acute coronary syndrome within 6 months prior to starting drug therapy\n  * Uncontrolled angina despite medical therapy (Canadian Cardiovascular Society grade II-IV despite medical therapy\n  * Symptomatic heart failure NYHA Class II-IV prior or current cardiomyopathy or severe valvular disease\n  * Prior or current cardiomyopathy including but not limited to the following: Known hypertrophic cardiomyopathy; Known arrhythmogenic right ventricular cardiomyopathy; or Previous moderate or severe impairment of left ventricular systolic function (LVEF \\\u003C45% on echocardiography or equivalent of MUGA) even if full recovery has occurred\n  * Atrial fibrillation with a ventricular rate of \\>100 beats per minute on ECG at rest\n* Uncontrolled infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Active primary immunodeficiency\n* Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome, or renal tubular acidosis.\n* Current gastrointestinal conditions such as refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of small bowel, symptomatic inflammatory bowel disease, or ulcerative colitis, or partial or complete bowel obstruction.\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease (colitis, Crohn's), celiac disease, systemic lupus erythematosus, Wegener syndrome, myasthenia gravis, Graves' disease, rheumatoid arthritis, uveitis.\n\nThe following exceptions are:\n\n* Patients with vitiligo or alopecia\n* Patients with hypothyroidism (e.g., following Hashimoto's syndrome) stable on hormone replacement\n* Psoriasis that does not require systemic therapy\n* Patients with celiac disease that is controlled by diet alone\n\n  • Ophthalmological conditions as follows:\n* Current or past history of retinal vein occlusion\n* Known intraocular pressure (IOP)\\>21 mmHg (or ULN adjusted by age) or uncontrolled glaucoma.\n* Subjects with ophthalmological findings secondary to long standing optic pathway glioma (such as visual loss, optic nerve pallor, or strabismus) or long standing orbito-temporal PN (such as vision loss, strabismus) will not be considered a significant abnormality for purposes of this study.\n\nAny Supplementation with vitamin E.\n\nHypersensitivity to investigational products, or drugs with similar chemical structures to investigational products.\n\nPatients unwilling or unable to comply with the protocol.\n\nWhile not an exclusion criterion, unless clinically indicated, patients should avoid taking other additional non-study medications that may interfere with the study medications. In particular, participants should avoid medications that are known to either induce or inhibit the hepatic activity of CYP1A2, CYP2C19, and CYP3A4.","99 Years",{"count":720,"type":19},41,[378],"A multi-institutional open-label phase 1\u002F2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory\u002Funresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory\u002Frelapsed sarcomas. The phase 2 portion will be for patients with refractory\u002Funresectable NF1-associated MPNST.",[724,725,27],"MPNST","NF1",[724,727,725,295],"Neurofibromatosis 1","2026-07-10",{"date":652,"type":32},{"date":731,"type":19},"2026-11-15",{"date":733,"type":19},"2032-11-15",{"name":735,"class":39},"University of Alabama at Birmingham",{"id":737,"slug":738,"hasResults":12,"nctId":739,"briefTitle":740,"officialTitle":740,"acronym":741,"eligibilityCriteria":742,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":743,"targetDuration":4,"studyType":50,"phases":744,"briefSummary":745,"conditions":746,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":749,"lastUpdatePostDateStruct":750,"startDateStruct":752,"completionDateStruct":754,"leadSponsor":756,"locationsCount":40},"100524050","locally-ablative-therapy-in-oligo-progressive-solid-tumors-valorous-100524050","NCT06103669","Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)","VALOROUS","Inclusion Criteria:\n\n1. Must have one of the following histologically and\u002For biochemically confirmed genitourinary malignancies:\n\n   1. Cohort A: Breast Malignancy\n   2. Cohort B: Gynecological Malignancy\n   3. Cohort C: Head and Neck Malignancies\n   4. Cohort D: Sarcomas\n   5. Cohort E: Other solid malignancy specified in the protocol\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age ≥18 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \\[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\\]\n7. ≤ 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and\u002F interventional radiologist.\n\nExclusion Criteria:\n\n1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.",{"count":101,"type":19},[52],"This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.",[122,747,188,27,748],"Oligoprogressive","Other Cancer","2026-07-06",{"date":751,"type":32},"2026-07-08",{"date":753,"type":32},"2023-10-05",{"date":755,"type":19},"2033-12",{"name":757,"class":39},"University of California, Davis"]